FUCHS (XTRA:FPE3) Q3 Results Strengthen Profit Growth As Cash Questions Linger

Fuchs came into today as a quietly efficient compounder in lubricants and specialty chemicals, trading at €44.28 after a 7‑day slip of about 2% and a solid 3‑month climb of roughly 9%. The Q3 2026 release then landed with a very different message. Revenue for the quarter reached €1,123m and net income hit €103m, marking the strongest profitability trend in the recent run of results. If the share price looked cautious, the earnings print looked anything but timid, which puts the spotlight on whether the market is underpricing that profit momentum.

If you like how Fuchs is quietly turning solid profitability into a stronger earnings profile but want a wider bench of similar quality industrials with sturdy balance sheets and earnings power to compare it with, line it up against our curated list in the list of solid balance sheet and fundamentals stocks (199 results).

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): €1,123m vs €896m (higher year on year)
• Net Income (Excl. Extra Items, Q3 2026 vs Q3 2025): €103m vs €84m (higher year on year)
• Basic EPS (Trailing 12 Months to Q3 2026 vs TTM to Q3 2025): €2.60 vs €2.22 (higher year on year)
• Net Profit Margin (TTM to Q3 2026 vs TTM to Q3 2025): 9.0% vs 8.3% (margin improved)

Earnings tell part of the story, but anyone focused on valuation knows the real test is whether cash flows support the current share price. Looking at Fuchs' cash generation on its own, the stock could be a hefty 35% undervalued.

Fuchs execution: Asia and programs under the microscope

For the upbeat view to hold, Fuchs needs its growth engines and programs to actually move the needle.

"Expansion of Fuchs in Asia Pacific, including stronger contributions from China, Australia, India, Turkey and Africa, is expected to increase the share of higher growth regions in the mix and support revenue and EBIT progression."

Asia Pacific EBIT growth of 28% and record group EBIT of €149m in Q3 point in the right direction. China and Australia did the heavy lifting, while EMEA and the Americas also contributed. Raised full year guidance to about €4.1b sales and €500m EBIT shows FUCHS100 and Transform2Grow are at least translating into improved profitability today.

Fuchs risks: margin resilience and cash strain tested

The more cautious view focuses on mix, input costs and cash generation pressure.

"Ongoing inflation and higher personnel and raw material costs, including tight supply for key inputs such as Group III base oils and PAO, may prove harder to offset with price increases and efficiency gains. This would weigh on free cash flow, net margins and ultimately earnings."

Gross margin slipped to 34.3%, slightly below the roughly 35% ambition, which shows pricing is not fully offsetting input inflation. Free cash flow before acquisitions was €92m with net operating working capital above €1b, and guidance still flags free cash flow significantly below €270m for 2026. Earnings are strong, but cash remains under pressure.

One Narrative disagrees with today's price. → See where this Narrative says Fuchs should trade.

Hunt For Quiet Mispricings

Fuchs just showed how strong results and a hesitant share price can sit side by side. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 47% below our estimate - use a new integration to reduce domestic reliance and target higher margin export volumes.
• Company 2 - 23% below our estimate - move more shoppers into higher value packaged staples and drinks as branded mix deepens.
• Company 3 - 43% below our estimate - convert new defense and public safety frameworks into wider system orders for communication equipment.

Three companies from the same screener. Open the full list of 196 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com